Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Recruiting, any sponsor type, condition "tardive dyskinesia"
By trial status
The same filters, counted in each status. Pick one to switch.
5 trials
Showing 1 to 5, recently updated first.
- Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07365462 · 100 participants (planned) · Start Feb 6, 2026 · Primary completion Feb 2027
Drug: NBI-1065890; Placebo · For: Tardive Dyskinesia
Sites: Bryant, Arkansas; Chino, California; Fountain Valley, California · 48 sites in all
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07105111 · 100 participants (planned) · Start Aug 29, 2025 · Primary completion Jun 2028
Drug: Valbenazine · For: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder and 2 more
Sites: Bryant, Arkansas; Chino, California; Fresno, California · 19 sites in all
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental DisabilitiesRecruiting
University Hospitals Cleveland Medical CenterAcademic, hospital or other
NCT06997198 · 25 participants (planned) · Start Jun 22, 2026 · Primary completion Oct 1, 2027
Drug: Deutetrabenazine Oral Capsule · For: Tardive Dyskinesia; Intellectual Disability; Developmental Disabilities
Sites: Cleveland, Ohio
- Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaPivotal-lookingRecruiting
Luye Pharma Group Ltd.Industry
NCT06731868 · 120 participants (planned) · Start Jan 14, 2025 · Primary completion Oct 31, 2025
Drug: LPM3770164 sustained release tablet 5 mg; LPM3770164 sustained release tablet 10 mg and 2 more · For: Tardive Dyskinesia (TD)
Sites: Shanghai, China
Corporal Michael J. Crescenz VA Medical CenterFederal agency
NCT03495024 · 10 participants (planned) · Start Jan 1, 2019 · Primary completion Apr 30, 2020
Drug: Varenicline · For: Schizophrenia; Schizoaffective Disorder; Tobacco Smoking and 2 more
Sites: Philadelphia, Pennsylvania
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.